Literature DB >> 6336888

Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.

S E Kabawat, R C Bast, W R Welch, R C Knapp, R B Colvin.   

Abstract

A murine monoclonal antibody, OC125, reacts with a surface component of ovarian tumor cells from humans, but fails to react with normal adult ovarian cells. The spectrum of reactivity of OC125 in ovarian tumors from humans was defined by testing cryostat tissue sections from 60 selected ovarian tumors by indirect immunofluorescence. OC125 stained 7/7 benign, and borderline serous ovarian tumors, 19/23 (83%) serous adenocarcinomas, 2/2 mixed serous and endometrioid carcinomas, 2/3 endometrioid carcinomas, 1/4 clear cell carcinomas, and 2/2 undifferentiated carcinomas. No reactivity was found in eight mucinous ovarian tumors or any of the other 11 epithelial sex cord, germ cell, on hematopoietic tumors tested. In neoplastic cysts, papillae, and glands, the staining was most intense on the luminal surface or in subjacent cytoplasm. Cells in solid sheets also showed peripheral staining. Within a reactive tumor, both negative and positive cells could be found, intimately intermixed. There were no differences in these staining patterns between tissues from primary and metastatic sites. The expression of the OC125 antigen was not related to the degree of malignancy as judged by pathologic criteria. Although mucinous tumors lacked reactivity with OC125, seven of eight mucinous adenomas and adenocarcinomas bound a monoclonal antibody against carcinoembryonic antigen (CEA). Thus, OC125 recognizes a common antigen in some but not all ovarian tumors of serous, clear cell, endometrioid, or undifferentiated type. OC125 may prove useful in the pathologic and cytologic identification of certain types of ovarian tumor cells. Its lack of reactivity with mucinous tumors suggests these belong in a distinct subgroup of ovarian epithelial tumors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6336888     DOI: 10.1093/ajcp/79.1.98

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  46 in total

1.  Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer.

Authors:  F Kraeber-Bodéré; A Mishra; P Thédrez; A Faivre-Chauvet; M Bardiès; S Imai; J Le Boterff; J F Chatal
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Unreviewed reports.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-13

3.  Monoclonal antibodies against human ovarian tumor associated antigen NB/70K: preparation and use in a radioimmunoassay for measuring NB/70K in serum.

Authors:  S Knauf; J Kalwas; B F Helmkamp; L W Harwell; J Beecham; E M Lord
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Use of immunohistochemical staining panel for characterisation of ovarian neoplasms.

Authors:  P Ashorn; M Helle; H Helin; R Ashorn; K Krohn
Journal:  J Clin Pathol       Date:  1988-01       Impact factor: 3.411

5.  MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling.

Authors:  Panagiota Giannakouros; Marina Comamala; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

6.  Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease.

Authors:  I Fukazawa; N Inaba; Y Ota; N Sato; S Shirotake; H Iwasawa; T Sato; H Takamizawa; B Wiklund
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

7.  Radioimmunoscintigraphy of ovarian cancer with 131-iodine labeled OC-125 antibody fragments.

Authors:  G Barzen; A C Mayr; M Langer; R Becker; M Cordes; C Zwicker; K Koppenhagen; R Felix
Journal:  Eur J Nucl Med       Date:  1989

8.  Immunohistochemical reactivity of a monoclonal antibody prepared against human breast carcinoma.

Authors:  R Mariani-Costantini; M I Colnaghi; F Leoni; S Mènard; S Cerasoli; F Rilke
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

9.  Immunohistochemical characterization of undifferentiated carcinomas of the ovary.

Authors:  Y Kuwashima; T Uehara; K Kishi; K Shiromizu; M Matsuzawa; S Takayama
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer.

Authors:  Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  J Ovarian Res       Date:  2010-01-18       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.